INTRODUCTION {#s1}
============

Sarcomas are a family of rare malignant tumors arising from bone and soft tissues with more than 50 different histologies accounting for about 1-2% of cancers in adults and 15-20% in children (worldwide incidence: approximately 200,000 cases per year). The pathogenesis of sarcomas is multifactorial including environmental (such as exposure to ionizing radiations or chemical carcinogens) and genetic components, although the disease rarity represents an objective hurdle to the research in this field of investigation. Significant advances have been made in the understanding of the acquired genetic events leading to sarcomagenesis. It has been recognized that three types of somatic DNA alterations, translocations, mutations, and copy number variations, play a key role in these tumors \[[@R1]\]. As a consequence, sarcomas are grouped into two categories: balanced translocation associated sarcomas (BATS) and complex genotype/karyotype sarcomas (CGKS), which are characterized by a stable genome and genomic instability, respectively \[[@R2]\]. A potential therapeutic implication of such genetic taxonomy classification is that some recurrent chromosomal translocations might be exploited for the development of drugs targeting the protein products of fusion oncogenes \[[@R1]\].

Conversely, knowledge on the role of germline DNA variations in sarcomagenesis is sparse and limited. Although a minority of sarcomas arise within well characterized heritable cancer predisposition syndromes (e.g., osteosarcoma and Bloom syndrome, desmoid tumors and familial adenomatous polyposis) \[[@R3]\], the vast majority of sarcomas occur sporadically and the role of the genetic background in their pathogenesis is to be uncovered. Recent advances in molecular high-throughput technology, which conduct of genome wide association studies (GWAS), is accelerating the pace of discovery of sarcoma predisposition loci.

Looking at the already existing international literature, some investigators have meta-analyzed the evidence regarding a handful of SNPs such as *XRCC3* rs861539 \[[@R4]\], *MDM2* rs2279744 \[[@R5], [@R6]\], and *CTLA4* rs231775 \[[@R7]\]: however, to the best of our knowledge no comprehensive collection of the available data in this field of oncology has been published thus far.

With the present work we systematically reviewed and meta-analyzed the available evidence in this field in order to: 1) provide readers with the first knowledgebase dedicated to the relationship between germline DNA variation and sarcoma risk; 2) identify areas lacking of meaningful information thus helping to inform future studies; and 3) suggest a biological interpretation of current findings utilizing network and pathway analysis \[[@R8]\] after integrating multiple sources of biological data \[[@R9]\].

RESULTS {#s2}
=======

Characteristics of the eligible studies {#s2_1}
---------------------------------------

We identified 90 eligible articles, comprising 47,796 subjects, 14,358 cases and 33,438 controls. The details of the literature search are summarized in Figure [1](#F1){ref-type="fig"}.

![Flow diagram summarizing the search strategy and the study selection process](oncotarget-09-18607-g001){#F1}

Based on the prevalent ancestry (ie. the race of at least 80% of the enrolled subjects) the majority of the studies were Asian (N=57 studies) the rest being Caucasian (N=25 studies), or mixed (N=8 studies). Based on study design, half of included studies were population based case-controls studies (N=40 studies), the remaining were hospital based (N=39 studies), with a few (N=11) being mixed or not specified. Two studies were GWAS \[[@R10], [@R11]\].

According to histology, the majority of the eligible studies investigated bone tumors (N=65) and the remaining investigated Ewing\'s sarcoma (N=9), soft tissue sarcomas (N=6), chordoma (N=4), hemangiosarcoma (N=1), and mixed sarcomas (N=5). Thirteen studies investigated pediatric subjects or young adults. Although pediatric/young age ranged from 0 to 35 years old in eligible studies, most of the studies considered subjects \< 20 years old.

We evaluated the included studies following the criteria of the Newcastle-Ottawa scale (NOS) scoring system. The mean score was 7.8. The main features of all the eligible studies and the NOS score are available on Table [1](#T1){ref-type="table"}.

###### Characteristics of the included studies and Newcastle-Ottawa quality assessment (NOS) evaluation

  Included articles references         Subjects characteristics           NOS                                                                                        
  ------------------------------------ ---------------------------------- ------ --------------------- ----- ------ -------------- ----------- --------------- ----- ---
  Adiguzel M. \[[@R12]\]               Indian J Exp Biol                  2016   Bone tumors           54    81     Adult          Caucasian   Population      413   8
  Alhopuro P. \[[@R13]\]               J Med Genet                        2005   Soft tissue sarcoma   68    185    Adult          Caucasian   Population      413   8
  Almeida PSR. \[[@R14]\]              Genet Mol Res                      2008   Soft tissue sarcoma   100   85     Adult          Mixed       not specified   213   6
  Aoyama T. \[[@R15]\]                 Cancer Letters                     2002   Bone tumors           38    72     Adult          Asian       Population      313   7
  Barnette P. \[[@R16]\]               Cancer Epidemiol Biomarkers Prev   2004   Mixed                 42    326    Pediat/Young   Caucasian   Population      323   8
  Biason P. \[[@R17]\]                 Pharmacogenomics J                 2012   Bone tumors           130   250    Adult          Caucasian   Hospital        323   8
  Bilbao-Aldaiturriaga N. \[[@R18]\]   Pediatr Blood Cancer               2015   Bone tumors           99    387    Pediat/Young   Caucasian   Hospital        323   8
  Chen Y. \[[@R19]\]                   Tumor Biol                         2016   Bone tumors           190   190    Adult          Asian       Hospital        323   8
  Cong Y. \[[@R20]\]                   Tumor Biol                         2015   Bone tumors           203   406    Adult          Asian       Hospital        323   8
  Cui Y. \[[@R21]\]                    Biomarkers                         2016   Bone tumors           251   251    Adult          Asian       Hospital        323   8
  Cui Y. \[[@R22]\]                    Tumor Biol                         2016   Bone tumors           260   260    Adult          Asian       Hospital        323   8
  Dong YZ. \[[@R23]\]                  Genet Mol Res                      2015   Bone tumors           185   201    Adult          Asian       Hospital        323   8
  DuBois SG. \[[@R24]\]                Pediatr Blood Cancer               2011   Ewing\'s sarcoma      135   200    Pediat/Young   Caucasian   Hospital        213   6
  Ergen A. \[[@R25]\]                  Mol Biol Rep                       2011   Bone tumors           50    50     Adult          Caucasian   not specified   313   7
  Feng D. \[[@R26]\]                   Genet Test Mol Biomarkers          2013   Ewing\'s sarcoma      308   362    Adult          Asian       Hospital        323   8
  Gloudemans T. \[[@R27]\]             Cancer Res                         1993   Soft tissue sarcoma   9     26     Adult          Caucasian   Population      303   6
  Grochola LF. \[[@R28]\]              Clin Cancer Res                    2009   Soft tissue sarcoma   130   497    Adult          Caucasian   Population      313   7
  Grünewald TG. \[[@R29]\]             Nat Genet                          2015   Ewing\'s sarcoma      343   251    Adult          Caucasian   Population      423   9
  Guo J. \[[@R30]\]                    Genet Mol Res                      2015   Bone tumors           136   136    Adult          Asian       Hospital        313   7
  He J. \[[@R31]\]                     Endocr J                           2013   Bone tumors           415   431    Adult          Asian       Hospital        323   8
  He J. \[[@R32]\]                     Endocrine                          2014   Bone tumors           415   431    Adult          Asian       Hospital        323   8
  He M. \[[@R33]\]                     Tumor Biol                         2014   Bone tumors           189   195    Adult          Asian       Hospital        323   8
  He ML. \[[@R34]\]                    Asian Pac J Cancer Prev            2013   Bone tumors           59    63     Adult          Asian       Hospital        313   7
  He Y. \[[@R35]\]                     Int Orthop                         2014   Bone tumors           120   120    Adult          Asian       Hospital        323   8
  Hu GL. \[[@R36]\]                    Genet Mol Res                      2015   Bone tumors           130   130    Adult          Asian       Hospital        323   8
  Hu YS. \[[@R37]\]                    BMC Cancer                         2010   Bone tumors           168   168    Adult          Asian       Population      423   9
  Hu YS. \[[@R38]\]                    Med Oncol                          2011   Bone tumors           168   168    Adult          Asian       Population      423   9
  Hu Z. \[[@R39]\]                     Genet Test Mol Biomarkers          2015   Bone tumors           368   370    Adult          Asian       not specified   213   6
  Ito M. \[[@R40]\]                    Clin Cancer Res                    2010   Soft tissue sarcoma   155   37     Adult          Mixed       Hospital        203   5
  Jiang C. \[[@R41]\]                  Med Oncol                          2014   Bone tumors           168   216    Adult          Asian       Hospital        323   8
  Kelley MJ. \[[@R42]\]                Hum Genet                          2014   Chordoma              103   160    Adult          Asian       Population      413   8
  Koshkina NV. \[[@R43]\]              J Pediatr Hematol Oncol            2007   Bone tumors           123   510    Pediat/Young   Mixed       Population      413   8
  Le Morvan V. \[[@R44]\]              Int J Cancer                       2006   Mixed                 93    53     Adult          Caucasian   Population      403   7
  Li L. \[[@R45]\]                     Genet Mol Res                      2015   Bone tumors           52    100    Adult          Asian       Hospital        312   6
  Liu Y. \[[@R46]\]                    DNA Cell Biol                      2011   Bone tumors           267   282    Adult          Asian       Population      313   7
  Liu Y. \[[@R47]\]                    PloSONE                            2012   Bone tumors           326   433    Adult          Asian       Population      423   9
  Lu H. \[[@R48]\]                     Tumor Biol                         2015   Bone tumors           388   388    Adult          Asian       Hospital        323   8
  Lu XF. \[[@R49]\]                    Asian Pac J Cancer Prev            2011   Bone tumors           110   226    Adult          Asian       Hospital        313   7
  Lv H. \[[@R50]\]                     Mol Med Rep                        2014   Bone tumors           103   201    Adult          Asian       Hospital        213   6
  Ma X. \[[@R51]\]                     Genet Mol Res                      2016   Bone tumors           141   282    Adult          Asian       Hospital        223   7
  Martinelli M. \[[@R52]\]             Oncotarget                         2016   Ewing\'s sarcoma      100   147    Pediat/Young   Caucasian   Population      423   9
  Mei JW. \[[@R99]\]                   Int J Clin Exp Pathol              2016   Bone tumors           97    120    Adult          Asian       Population      313   7
  Miao C.\[[@R53]\]                    Sci Rep                            2015   Soft tissue sarcoma   138   131    Adult          Asian       Hospital        223   7
  Mirabello L. \[[@R54]\]              Carcinogenesis                     2010   Bone tumors           99    1430   Adult          Caucasian   mixed           323   8
  Mirabello L. \[[@R55]\]              BMC Cancer                         2011   Bone tumors           96    1426   Adult          Caucasian   mixed           323   8
  Nakayama R. \[[@R56]\]               Cancer Sci                         2008   Mixed                 544   1378   Adult          Asian       mixed           323   8
  Naumov VA. \[[@R57]\]                Bull Exp Biol Med                  2012   Bone tumors           68    96     Adult          Caucasian   not specified   313   7
  Oliveira ID. \[[@R58]\]              J Pediatr Hematol Oncol            2007   Bone tumors           80    160    Pediat/Young   Mixed       Hospital        323   8
  Ozger H. \[[@R59]\]                  Folia Biologica (Praha)            2008   Mixed                 56    44     Adult          Caucasian   Population      403   7
  Patino-Garcia A. \[[@R60]\]          J Med Genet                        2000   Bone tumors           110   111    Pediat/Young   Caucasian   not specified   323   8
  Pillay N. \[[@R61]\]                 Nat Genet                          2012   Chordoma              40    358    Adult          Caucasian   population      323   8
  Postel-Vinay S. \[[@R10]\]           Nat Genet                          2012   Ewing\'s sarcoma      401   4352   Adult          Caucasian   population      423   9
  Qi Y. \[[@R62]\]                     Tumor Biol                         2016   Bone tumors           206   206    Adult          Asian       Hospital        323   8
  Qu WR. \[[@R63]\]                    Genetic Mol Res                    2016   Bone tumors           153   252    Adult          Asian       Hospital        323   8
  Ru JY. \[[@R64]\]                    Int J Clin Exp Pathol              2015   Bone tumors           210   420    Adult          Asian       Hospital        323   8
  Ruza E. \[[@R65]\]                   J Pediatr Hematol Oncol            2003   Mixed                 125   143    Pediat/Young   Caucasian   not specified   322   7
  Saito T. \[[@R66]\]                  Int J Cancer                       2000   Hemangiosarcoma       22    84     Adult          Mixed       Population      213   6
  Salinas-Souza C. \[[@R67]\]          Pharmacogenet Genomics             2010   Bone tumors           80    160    Pediat/Young   Mixed       Hospital        323   8
  Savage SA. \[[@R68]\]                Cancer Epidemiol Biomarkers Prev   2007   Bone tumors           104   74     Pediat/Young   Caucasian   Hospital        213   6
  Savage SA. \[[@R69]\]                Pediatr Blood Cancer               2007   Bone tumors           104   74     Pediat/Young   Caucasian   Hospital        213   6
  Savage SA. \[[@R11]\]                Nat Genet                          2013   Bone tumors           941   3291   Adult          Caucasian   Population      423   9
  Shi ZW. \[[@R70]\]                   Cancer Biomark                     2016   Bone tumors           174   150    Adult          Asian       Hospital        313   7
  Silva DS. \[[@R71]\]                 Gene                               2012   Ewing\'s sarcoma      24    200    Adult          Mixed       Population      323   8
  Tang YJ. \[[@R72]\]                  Medicine                           2014   Bone tumors           160   250    Adult          Asian       Population      423   9
  Thurow HS. \[[@R73]\]                Mol Biol Rep                       2013   Ewing\'s sarcoma      24    91     Adult          Mixed       Population      323   8
  Tian Q. \[[@R74]\]                   Eur J Surg Oncol                   2013   Bone tumors           133   133    Adult          Asian       Population      423   9
  Tie Z. \[[@R75]\]                    Int J Clin Exp Pathol              2014   Bone tumors           165   330    Adult          Asian       Population      423   9
  Toffoli G. \[[@R76]\]                Clin Cancer Res                    2009   Bone tumors           201   250    Adult          Caucasian   Population      423   9
  Walsh KM. \[[@R77]\]                 Carcinogenesis                     2016   Bone tumors           660   6892   Pediat/Young   Caucasian   Population      423   9
  Wang J. \[[@R78]\]                   DNA Cell Biol                      2012   Ewing\'s sarcoma      158   212    Adult          Asian       Population      323   8
  Wang J. \[[@R79]\]                   DNA Cell Biol                      2013   Bone tumors           106   210    Adult          Asian       Population      323   8
  Wang K. \[[@R80]\]                   Biomed Rep                         2014   Chordoma              65    65     Adult          Asian       Population      313   7
  Wang K. \[[@R81]\]                   Tumor Biol                         2016   Bone tumors           126   168    Adult          Asian       Hospital        323   8
  Wang W. \[[@R82]\]                   DNA Cell Biol                      2011   Bone tumors           205   216    Adult          Asian       Hospital        323   8
  Wang W. \[[@R83]\]                   Genet Test Mol Biomarkers          2011   Bone tumors           205   215    Adult          Asian       Hospital        323   8
  Wang Z. \[[@R84]\]                   Tumor Biol                         2014   Bone tumors           330   342    Adult          Asian       Population      423   9
  Wu Y. \[[@R85]\]                     Tumor Biol                         2015   Bone tumors           124   136    Adult          Asian       Hospital        323   8
  Wu Z. \[[@R86]\]                     Int J Mol Sci                      2013   Chordoma              65    120    Adult          Asian       not specified   313   7
  Xin DJ. \[[@R87]\]                   Int J Clin Exp Pathol              2015   Bone tumors           90    100    Adult          Asian       Population      413   8
  Xu H. \[[@R88]\]                     Med Sci Monit                      2016   Bone tumors           279   286    Pediat/Young   Asian       Hospital        323   8
  Xu S. \[[@R89]\]                     DNA Cell Biol                      2014   Bone tumors           202   216    Adult          Asian       Population      423   9
  Yang L. \[[@R90]\]                   Int J Clin Exp Pathol              2015   Bone tumors           152   304    Adult          Asian       Population      423   9
  Yang S. \[[@R91]\]                   Genet Test Mol Biomarkers          2012   Ewing\'s sarcoma      223   302    Adult          Asian       Population      423   9
  Yang W. \[[@R92]\]                   Med Oncol                          2014   Bone tumors           118   126    Adult          Asian       not specified   323   8
  Zhang G. \[[@R93]\]                  Genet Mol Res                      2015   Bone tumors           180   360    Adult          Asian       Population      423   9
  Zhang HF. \[[@R94]\]                 Genet Mol Res                      2015   Bone tumors           182   182    Adult          Asian       Population      423   9
  Zhang N. \[[@R95]\]                  Onco Targets Ther                  2016   Bone tumors           276   286    Adult          Asian       Hospital        323   8
  Zhang Y. \[[@R96]\]                  Tumor Biol                         2014   Bone tumors           610   610    Adult          Asian       Population      423   9
  Zhao J. \[[@R97]\]                   BioMed Res Int                     2014   Bone tumors           247   428    Adult          Asian       Population      423   9
  Zhi LQ. \[[@R98]\]                   Tumor Biol                         2014   Bone tumors           212   240    Adult          Asian       Hospital        323   8

NOS: Newcastle-Ottawa quality assessment scale evaluation (0-9). NOS1: selection of the study groups (0-4); NOS2: comparability of the groups (0-2); NOS3: ascertainment of the exposure or outcome (0-3).

Characteristics of the retrieved genetic variants {#s2_2}
-------------------------------------------------

Overall, data on 1,126 polymorphisms involving 320 genes were retrieved. Variations were mainly SNPs, only six being insertion/deletions of more than one nucleotide. Based on the number of different genetic variations studied, the 11 most studied genes were the following: *EGR2* (179 different SNPs), *ADO* (58 different SNPs), *ZNF365* (40 different SNPs), *TRAPPC9* (28 different SNPs), *CASC8* (23 different SNPs), *CD99* (20 different SNPs), *EWSR1* (16 different SNPs) *TP53, HSD17B2* (15 different SNPs each) and *UGT1A8, LOC107984012* (12 different SNPs each).

Thirty-seven of these genetic variants were located no more than 2kb upstream the relevant gene, ten no more than 500bp downstream the relevant gene, 493 in introns, 100 in exons (non-UTRs), 19 in the 3'-UTR, seven in the 5'-UTR. Moreover, 413 SNPs were located in intergenic regions more than 2kb upstream or more than 500 bp downstream the relevant gene and 41 in non-coding transcripts. Among the exonic SNPs, 63 had a missense functional effect, while 37 were synonymous. Detailed information on all SNPs is reported in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Meta-analysis findings {#s2_3}
----------------------

At least two independent datasets were available for 51 genetic variations allowing us to perform 118 meta-analyses, 16 of them were histology-based meta-analysis on osteosarcoma and Ewing\'s sarcoma. Moreover, 13 sensitivity analysis were performed considering the ethnicity of the different datasets. The results of data meta-analyses are comprehensively reported in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}. Polymorphism "rs" identifier, nucleotide change and amino acid change are reported in [Supplementary Table 3](#SD4){ref-type="supplementary-material"}.

The eight most studied genetic variants were the following: *TP53* rs1042522 (6 datasets), *VEGF* rs3025039 and *GSTM1* deletion (5 datasets each), *CTLA4* rs231775, *CTLA4* rs5742909, *MDM2* rs2279744, rs10434 *VEGF* and *GSTT1* deletion (4 datasets each).

The number of subject (cases plus controls) enrolled in the 118 meta-analyses ranged from 144 to 5,347 (median: 1,195). Based on the number of subjects, the 10 most studied genetic variants, all with 5,347 subjects, were the following: *EGR2* rs224292 and rs224278, *ADO* rs1848797 and rs1509966, *MDM2* rs1690916, *LOC107984012* rs9633562, rs944684 and rs6479860, *ZNF365* rs11599754 and rs10761660.

Of the 118 meta-analyses and 13 sensitivity analysis (131 total analyses) performed, 55 resulted to be statistically significant (P-value \<0.05). The level of summary evidence, among the significant associations identified by meta-analysis, was high, intermediate, and low in 9, 38, and 8 analyses respectively. The most frequent single cause of non-high-quality level of evidence was between-study heterogeneity followed by the small sample size. Considering all statistically significant meta-analyses FPRP was optimal (\<0.2) at least at the 10E3 level for 10/55 analysis, 9 of them with high level of summary evidence.

The details of significant associations are reported in Table [2](#T2){ref-type="table"}.

###### Meta-analysis results: genetic variants significantly associated with sarcoma risk

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP ID       Genes                Analysis      Model        Sarcoma type   data\   Meta-analysis Ethnicity   OR \[95% CI\]          I ^2^ %   P value     Cases   Controls   Ref/ Alt         Venice Criteria   FPRP (E-03)   Level of Evidence
                                                                              sets                                                                                                                                               
  ------------ -------------------- ------------- ------------ -------------- ------- ------------------------- ---------------------- --------- ----------- ------- ---------- ---------------- ----------------- ------------- -------------------
  rs11599754   ZNF365, ADO          primary       Per allele   Ewing\'s       2       Caucasian                 1.48 \[1.32, 1.66\]    0         \<0.00001   744     4603       T/C              AAA               Y             HIGH

  rs1509966    ADO, EGR2            primary       Per allele   Ewing\'s       2       Caucasian                 1.58 \[1.42, 1.77\]    0         \<0.00001   744     4603       A/G              AAA               Y             HIGH

  rs1848797    ADO, EGR2            primary       Per allele   Ewing\'s       2       Caucasian                 1.57 \[1.4, 1.77\]     0         \<0.00001   744     4603       G/A              AAA               Y             HIGH

  rs224278     EGR2                 primary       Per allele   Ewing\'s       2       Caucasian                 1.73 \[1.49, 2.02\]    0         \<0.00001   744     4603       T/C              AAA               Y             HIGH

  rs9633562    EGR2, LOC107984012   primary       Per allele   Ewing\'s       2       Caucasian                 1.46 \[1.29, 1.65\]    0         \<0.00001   744     4603       A/C              AAA               Y             HIGH

  rs10761660   ADO, EGR2            primary       Per allele   Ewing\'s       2       Caucasian                 1.39 \[1.21, 1.6\]     0         \<0.00001   744     4603       T/C              AAA               Y             HIGH

  rs224292     ADO, EGR2            primary       Per allele   Ewing\'s       2       Caucasian                 1.67 \[1.42, 1.96\]    0         \<0.00001   744     4603       A/G              AAA               Y             HIGH

  rs231775     CTLA4                primary       Per allele   Mixed          4       Asian                     1.36 \[1.2, 1.54\]     0         \<0.00001   1003    1162       G/A              AAA               Y             HIGH

  rs454006     PRKCG                primary       Per allele   Osteo          2       Asian                     1.35 \[1.18, 1.54\]    0         \<0.0001    998     998        T/C              AAA               Y             HIGH

  rs944684     LOC107984012         primary       Per allele   Ewing\'s       2       Caucasian                 1.73 \[1.4, 2.14\]     49        \<0.00001   744     4603       C/T              ABA               Y             INTERM

  rs2305089    T                    sensitivity   Per allele   Chordoma       2       Caucasian                 3.91 \[2.4, 6.38\]     47        \<0.00001   163     881        G/A              ABA               N             INTERM

  rs1042522    TP53                 primary       Dominant     Mixed          6       Mixed                     0.67 \[0.53, 0.84\]    0         0.0007      788     950        G/C              AAA               N             INTERM

  rs1042522    TP53                 subgroup      Dominant     Osteo          3       Mixed                     0.6 \[0.43, 0.84\]     15        0.002       509     737        G/C              AAA               N             INTERM

  rs1129055    CD86                 primary       Recessive    Mixed          2       Asian                     0.6 \[0.41, 0.88\]     0         0.008       363     428        A/G              BAA               N             INTERM

  rs11737764   NUDT6                primary       Dominant     Bone tumor     2       Caucasian                 2.12 \[1.34, 3.37\]    0         0.001       164     1522       A/C              AAA               N             INTERM

  rs1690916    MDM2                 primary       Per allele   Ewing\'s       2       Caucasian                 0.62 \[0.46, 0.83\]    0         0.001       164     1522       C/T              AAA               N             INTERM

  rs17206779   ADAMTS6              primary       Per allele   Osteo          2       Mixed                     0.79 \[0.67, 0.93\]    35        0.004       1109    3507       C/T              ABA               N             INTERM

  rs17655      ERCC5                primary       Recessive    Mixed          2       Caucasian                 2.04 \[1.07, 3.9\]     0         0.03        223     515        G/C              BAA               N             INTERM

  rs1799793    ERCC2                primary       Per allele   Osteo          2       Mixed                     0.75 \[0.58, 0.97\]    23        0.03        271     532        G/A              BAA               N             INTERM

  rs1799793    ERCC2                primary       Dominant     Osteo          2       Mixed                     0.63 \[0.44, 0.89\]    0         0.009       271     532        G/A              BAA               N             INTERM

  rs1800896    IL10                 primary       Per allele   Osteo          2       Mixed                     1.33 \[1.06,1.66\]     0         0.01        340     420        A/G              BAA               N             INTERM

  rs1906953    GRM4                 sensitivity   Per allele   Osteo          2       Asian                     0.68 \[0.55, 0.84\]    0         0.0004      294     384        G/A              BAA               N             INTERM

  rs2279744    MDM2                 primary       Per allele   Mixed          4       Mixed                     1.36 \[1.06, 1.76\]    26        0.02        448     563        T/G              ABA               N             INTERM

  rs2279744    MDM2                 primary       Recessive    Mixed          4       Mixed                     1.58 \[1.03, 2.42\]    20        0.04        448     563        T/G              AAA               N             INTERM

  rs2279744    MDM2                 primary       Dominant     Mixed          4       Mixed                     1.55 \[1.05, 2.29\]    36        0.03        448     563        T/G              ABA               N             INTERM

  rs231775     CTLA4                primary       Recessive    Mixed          4       Asian                     2 \[1.53, 2.62\]       0         \<0.00001   1003    1162       G/A              AAA               N             INTERM

  rs231775     CTLA4                primary       Dominant     Mixed          4       Asian                     1.35 \[1.14, 1.61\]    0         0.0007      1003    1162       G/A              AAA               N             INTERM

  rs231775     CTLA4                subgroup      Per allele   Ewing\'s       2       Asian                     1.36 \[1.15, 1.61\]    0         0.0003      531     664        G/A              AAA               N             INTERM

  rs231775     CTLA4                subgroup      Recessive    Ewing\'s       2       Asian                     2 \[1.39, 2.89\]       0         0.0002      531     664        G/A              AAA               N             INTERM

  rs231775     CTLA4                subgroup      Dominant     Ewing\'s       2       Asian                     1.36 \[1.07, 1.72\]    0         0.01        531     664        G/A              AAA               N             INTERM

  rs231775     CTLA4                subgroup      Per allele   Osteo          2       Asian                     1.36 \[1.13, 1.64\]    0         0.001       472     498        G/A              ABA               N             INTERM

  rs231775     CTLA4                subgroup      Recessive    Osteo          2       Asian                     2 \[1.34, 2.98\]       0         0.0007      472     498        G/A              ABA               N             INTERM

  rs231775     CTLA4                subgroup      Dominant     Osteo          2       Asian                     1.35 \[1.04, 1.75\]    0         0.02        472     498        G/A              ABA               N             INTERM

  rs3025039    VEGFA                primary       Per allele   Osteo          5       Asian                     1.28 \[1.12, 1.47\]    0         0.0004      987     1344       C/T              AAA               N             INTERM

  rs3025039    VEGFA                primary       Recessive    Osteo          5       Asian                     1.65 \[1.19, 2.27\]    6         0.002       987     1344       C/T              AAA               N             INTERM

  rs3025039    VEGFA                primary       Dominant     Osteo          5       Asian                     1.24 \[1.04, 1.47\]    0         0.02        987     1344       C/T              AAA               N             INTERM

  rs454006     PRKCG                primary       Recessive    Osteo          2       Asian                     1.99 \[1.54, 2.58\]    0         \<0.0001    998     998        T/C              AAA               N             INTERM

  rs6599400    FGFR3                primary       Per allele   Osteo          2       Caucasian                 1.53 \[1.19, 1.97\]    0         0.001       164     1522       C/A              AAA               N             INTERM

  rs699947     VEGFA                primary       Per allele   Osteo          2       Asian                     1.46 \[1.19, 1.79\]    0         0.0003      347     512        C/A              BAA               N             INTERM

  rs699947     VEGFA                primary       Recessive    Osteo          2       Asian                     1.73 \[1.17, 2.55\]    0         0.006       347     512        C/A              BAA               N             INTERM

  rs699947     VEGFA                primary       Dominant     Osteo          2       Asian                     1.51 \[1.14, 2\]       0         0.004       347     512        C/A              BAA               N             INTERM

  rs820196     RECQL5               primary       Recessive    Osteo          2       Asian                     2.15 \[1.41, 3.29\]    0         0.0004      397     441        T/C              BAA               N             INTERM

  rs820196     RECQL5               primary       Dominant     Osteo          2       Asian                     1.49 \[1.12, 1.98\]    0         0.006       397     441        T/C              BAA               N             INTERM

  rs861539     XRCC3, KLC1          primary       Per allele   Osteo          2       Asian                     1.57 \[1.25, 1.97\]    0         0.0001      288     440        C/T              BAA               N             INTERM

  rs861539     XRCC3, KLC1          primary       Recessive    Osteo          2       Asian                     2.23 \[1.4, 3.57\]     0         0.0008      288     440        C/T              BAA               N             INTERM

  rs861539     XRCC3, KLC1          primary       Dominant     Osteo          2       Asian                     1.57 \[1.16, 2.13\]    0         0.003       288     440        C/T              BAA               N             INTERM

  deletion     GSTT1                primary       Recessive    Mixed          4       Mixed                     1.32 \[1.01, 1.73\]    4         0.04        355     938        non-null/ null   AAA               N             INTERM

  rs1042522    TP53                 primary       Per allele   Mixed          6       Mixed                     0.6 \[0.39, 0.93\]     84        0.02        788     950        G/C              ACA               N             LOW

  rs1042522    TP53                 subgroup      Per allele   Osteo          3       Mixed                     0.47 \[0.23, 0.95\]    93        0.04        509     737        G/C              ACA               N             LOW

  rs1129055    CD86                 primary       Per allele   Mixed          2       Asian                     0.33 \[0.11, 1.01\]    93        0.05        363     428        A/G              BCA               N             LOW

  rs2305089    T                    primary       Per allele   Chordoma       3       Mixed                     2.87 \[1.35, 6.08\]    86        0.006       228     1001       G/A              ACA               N             LOW

  rs2305089    T                    primary       Recessive    Chordoma       2       Mixed                     4.16 \[1.21, 14.25\]   82        0.02        125     841        G/A              BCA               N             LOW

  rs6479860    LOC107984012 NRBF2   primary       Per allele   Ewing\'s       2       Caucasian                 1.79 \[1.36, 2.34\]    66        \<0.0001    744     4603       C/T              ACA               N             LOW

  rs7591996    GRM4                 primary       Per allele   Osteo          2       Mixed                     1.28 \[1.02, 1.61\]    53        0.03        1109    3507       A/C              ACA               N             LOW

  deletion     GSTM1                sensitivity   Recessive    Bone tumor     3       Asian                     1.69 \[1.02, 2.81\]    66        0.04        315     578        non-null/ null   BCA               N             LOW
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OR \[95%CI\]: Summary Odds Ratio \[95% Confidence Interval\]; Ref: reference allele; Alt: alternative allele; Venice criteria: A (high), B (moderate), C (weak) credibility for three parameters (amount of evidence, heterogeneity and bias); FPRP: false positive report probability at a prior probability of 10E-3; Y: noteworthy association (FPRP cut-off value 0.2), N: non noteworthy association; Level of evidence: overall level of summary evidence according to the Venice criteria and FPRP.

In order to provide an estimate of the impact of germline variants on sarcoma risk, the PAR (population attributable risk) was calculated. As an example, we considered the following three independent SNPs with high quality evidence on their relationship with sarcoma risk: rs11599754 of *ZNF365/EGR2* (chromosome 10, risk allele: C, risk allele frequency in European ancestry population: 0.39, meta-analysis OR: 1.48); rs231775 of *CTLA4* (chromosome 2, risk allele: A, risk allele frequency in European ancestry population: 0.65, meta-analysis OR: 1.36); and rs454006 of *PRKCG* (chromosome 19, risk allele: C, risk allele frequency in European ancestry population: 0.25, meta-analysis OR: 1.35). The PAR resulted equal to 37.2%.

Associations based on single studies {#s2_4}
------------------------------------

Beside the variations resulted to be statistically significantly associated with sarcoma risk in this meta-analysis, we retrieved from the included articles 906 SNPs statistically significantly associated with sarcoma risk (P-value \<0.05) based on single-study analysis. In Table [3](#T3){ref-type="table"} are reported 53 SNPs strongly associated with Ewing\'s sarcoma or osteosarcoma risk (P-value \<E-06), retrieved from the included studies.

###### Statistically significant associations based on single studies (P-value threshold E-06)

  Reference                    Cancer type   Genes                        SNP ID       Ref/Alt   Chr   OR \[95%CI\]          P-value    location               eQTL            eQTL P-value skeletal muscle
  ---------------------------- ------------- ---------------------------- ------------ --------- ----- --------------------- ---------- ---------------------- --------------- ------------------------------
  Postel-Vinay S. \[[@R10]\]   Ewing\'s      C1orf127, TARDBP             rs9430161    T/G       1     2.20 \[1.80, 2.70\]   1.40E-20   intergene                              
  Postel-Vinay S. \[[@R10]\]   Ewing\'s      C1orf127                     rs2003046    A/C       1     1.80 \[1.50, 2.20\]   1.30E-14   intron                                 
  Postel-Vinay S. \[[@R10]\]   Ewing\'s      C1orf127                     rs11576658   T/C       1     1.80 \[1.40, 2.30\]   9.40E-11   intron                                 
  Postel-Vinay S. \[[@R10]\]   Ewing\'s      SRP14-AS1                    rs4924410    C/A       15    1.50 \[1.30, 1.70\]   6.60E-09   intron                 RP11-521C20.2   1.60E-07
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs10995305   G/A       10    1.59 \[1.26, 2.00\]   4.38E-07   intergene              ADO             1.40E-16
  Zhao J. \[[@R97]\]           Osteo         ARHGAP35                     rs1052667    C/T       19    2.25 \[1.64, 3.09\]   4.43E-07   utr 3 prime            ARHGAP35        Other tissue
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224290     G/C       10    0.55 \[0.43, 0.70\]   7.80E-07   intergene              ADO             7.50E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224291     G/A       10    0.55 \[0.43, 0.70\]   7.80E-07   intergene              ADO             7.20E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224296     C/T       10    0.55 \[0.43, 0.70\]   7.80E-07   intergene              ADO             2.90E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224297     T/C       10    0.55 \[0.43, 0.70\]   7.80E-07   intergene              ADO             2.80E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224298     G/A       10    0.55 \[0.43, 0.70\]   7.80E-07   intergene              ADO             2.90E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224294     C/T       10    0.54 \[0.43, 0.69\]   1.01E-06   intergene              ADO             5.60E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224293     G/A       10    0.55 \[0.44, 0.71\]   1.02E-06   intergene              ADO             7.20E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, ADO                    rs1848796    C/T       10    1.80 \[1.42, 2.29\]   1.08E-06   intergene              ADO             2.90E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224282     A/G       10    0.55 \[0.44, 0.71\]   1.08E-06   intergene              ADO             7.20E-14
  Savage SA. \[[@R11]\]        Osteo         ADAMTS17                     rs2086452    T/C       15    1.35 \[1.19, 1.52\]   1.12E-06   intron                                 
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2                         rs648746     G/T       10    0.56 \[0.44, 0.71\]   1.21E-06   upstream               ADO             5.10E-15
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2                         rs648748     G/A       10    0.56 \[0.44, 0.71\]   1.21E-06   upstream               ADO             5.10E-15
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2                         rs7076924    A/G       10    1.79 \[1.41, 2.28\]   1.21E-06   upstream               ADO             5.50E-15
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2                         rs224277     T/C       10    0.56 \[0.44, 0.71\]   1.40E-06   upstream               ADO             3.30E-15
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224289     T/C       10    0.56 \[0.44, 0.71\]   1.42E-06   intergene              ADO             7.20E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs7096645    G/T       10    1.78 \[1.40, 2.27\]   1.54E-06   intergene              ADO             8.60E-14
  Grünewald TG. \[[@R29]\]     Ewing\'s      LOC107984012, NRBF2          rs10740101   A/G       10    2.07 \[1.55, 2.76\]   2.29E-06   intergene              ADO             4.90E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs7079482    C/T       10    2.06 \[1.54, 2.76\]   2.69E-06   intergene              ADO             1.70E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs1115705    T/C       10    2.07 \[1.55, 2.77\]   2.73E-06   intergene              ADO             9.40E-11
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs983319     A/T       10    2.07 \[1.55, 2.77\]   2.99E-06   intergene              ADO             4.10E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs1571918    A/G       10    2.05 \[1.54, 2.74\]   3.44E-06   intergene              ADO             2.80E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs1888968    C/T       10    2.05 \[1.54, 2.74\]   3.44E-06   intergene              ADO             1.90E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs1912369    G/A       10    2.05 \[1.54, 2.74\]   3.44E-06   intergene              ADO             3.50E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs4147153    A/G       10    2.05 \[1.54, 2.74\]   3.44E-06   intergene              ADO             3.50E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs4237316    C/T       10    2.05 \[1.54, 2.74\]   3.44E-06   intergene              ADO             1.90E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs4746746    C/T       10    2.05 \[1.54, 2.74\]   3.44E-06   intergene              ADO             7.20E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs6479854    C/T       10    2.05 \[1.54, 2.74\]   3.44E-06   intergene              ADO             1.50E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs7100213    T/C       10    2.05 \[1.54, 2.74\]   3.44E-06   intergene              ADO             2.10E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs4746745    T/C       10    2.03 \[1.52, 2.72\]   3.48E-06   intergene              ADO             5.90E-11
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224301     G/A       10    0.60 \[0.47, 0.76\]   3.67E-06   intergene              ADO             1.20E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224302     G/A       10    0.60 \[0.47, 0.76\]   3.67E-06   intergene              ADO             3.70E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs10822056   C/T       10    1.65 \[1.31, 2.09\]   3.70E-06   intergene              ADO             3.00E-13
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224295     A/C       10    0.60 \[0.48, 0.76\]   4.80E-06   intergene              ADO             1.50E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      ADO, EGR2                    rs224299     T/C       10    0.60 \[0.48, 0.76\]   4.80E-06   intergene              ADO             1.50E-10
  Savage SA. \[[@R11]\]        Osteo         LOC105373401, LOC105373402   rs13403411   C/T       2     1.30 \[1.16, 1.46\]   5.20E-06   intergene                              
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs1509952    C/T       10    2.06 \[1.54, 2.76\]   5.28E-06   intergene              ADO             3.50E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      LOC107984012                 rs10740095   T/C       10    2.03 \[1.52, 2.72\]   5.50E-06   intron                 ADO             4.20E-11
  Grünewald TG. \[[@R29]\]     Ewing\'s      LOC107984012                 rs925307     T/C       10    2.03 \[1.52, 2.72\]   5.50E-06   intron                 ADO             6.00E-11
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs7073383    A/G       10    2.01 \[1.50, 2.69\]   5.98E-06   intergene              ADO             1.60E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs10733780   G/T       10    2.01 \[1.50, 2.69\]   6.90E-06   intergene              ADO             2.90E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      LOC107984012                 rs7071512    T/C       10    2.01 \[1.50, 2.69\]   6.90E-06   intron                 ADO             4.20E-11
  Savage SA. \[[@R11]\]        Osteo         FAM208B, GDI2                rs2797501    A/G       10    0.62 \[0.51, 0.77\]   7.88E-06   missense, downstream                   
  Savage SA. \[[@R11]\]        Osteo         DLEU1, LOC107984568          rs573666     G/A       13    0.77 \[0.68, 0.86\]   8.59E-06   intergene              EBPL            Other tissue
  Grünewald TG. \[[@R29]\]     Ewing\'s      EGR2, LOC107984012           rs10740097   C/T       10    2.03 \[1.51, 2.72\]   9.03E-06   intergene              ADO             1.20E-10
  Grünewald TG. \[[@R29]\]     Ewing\'s      LOC107984012                 rs6479848    T/C       10    2.01 \[1.50, 2.69\]   9.16E-06   intron                 ADO             2.70E-11
  Grünewald TG. \[[@R29]\]     Ewing\'s      ZNF365, ADO, EGR2            rs224079     C/T       10    1.58 \[1.25, 2.01\]   9.24E-06   intergene              ADO             5.00E-22
  Grünewald TG. \[[@R29]\]     Ewing\'s      LOC107984012                 rs965128     C/T       10    1.99 \[1.49, 2.66\]   9.48E-06   intron                 ADO             3.10E-11

OR \[95%CI\]: Odds Ratio \[95% Confidence Interval\]; Ref: reference allele; Alt: alternative allele; eQTL: expression quantitative trait locus.

One dataset was available for each of those genetic variants. Although it was not possible to perform a meta-analysis, a strong association with sarcoma risk was found (P-values range from E-20 to E-06). Ewing\'s sarcoma associations in European and US European-descendant population mainly involved the candidate risk loci at 1p36.22, 10q21 reported by Postel-Vinay et al \[[@R10]\] GWAS and in the following related study of Grünewald et al \[[@R29]\]. The 1p36.22 variants associated with Ewing\'s sarcoma are located 25 kb proximal to the *TARDBP* gene. TARDBP (Tat activating regulatory DNA-binding protein, or TDP-43, transactive response DNA-binding protein) is a highly conserved DNA- and RNA-binding protein involved in RNA transcription and splicing. The 10q21 variants strongly associated with Ewing\'s sarcoma are located in a block containing four genes: *ADO* (encoding cysteamine dioxygenase), *ZNF365* (encoding zinc-finger protein 365), *EGR2* (encoding early growth response protein 2) and LOC107984012 (unknown function).

A further association with osteosarcoma in Guangxi population was studied by Zhao et al \[[@R97]\] regarding the Rho GTPase-activating protein 35 (ARHGAP35), a Rho family GTPase-activating protein. Finally Savage et al \[[@R11]\] GWAS found associations with osteosarcoma and GMR4 (glutamate receptor metabotropic 4), which were part of our meta-analysis and ADAMTS protein family, as ADAM Metallopeptidase with Thrombospondin Type 1 Motif 17. Of note, most statistically significant associations based on single studies did not have a statistically significant eQTL effect.

Network and pathway analysis findings {#s2_5}
-------------------------------------

Using the 36 genes whose SNPs were significantly associated with sarcoma risk (including data from both meta-analysis and single studies) and were also characterized by a significant eQTL effect, we found that the corresponding protein products interact with each other beyond chance (observed edges: 120; expected edges: 12; PPI enrichment P-value \<10E-20), with an average node degree equal to 6.7 (see Figure [2](#F2){ref-type="fig"}). Such enrichment indicates that the input molecules - as a whole group - are at least partially biologically connected. This high connectivity prompted us to conduct pathway analysis, which showed that the identified network is significantly enriched in DNA repair proteins, as shown in Table [4](#T4){ref-type="table"}.

![Network analysis of proteins encoded by genes whose variants associated with sarcoma risk and characterized by an expression quantitative trait locus effect (eQTL)\
The figure illustrates the high degree of connectivity of these proteins, which result to be enriched in DNA repair pathway components.](oncotarget-09-18607-g002){#F2}

###### Pathway analysis main findings: gene set enrichment analysis based on 36 sarcoma risk genes. Enrichments with at least ten overlapping genes are shown

  Pathway                                             Overlap   FDR           Genes                                                                                                              Database
  --------------------------------------------------- --------- ------------- ------------------------------------------------------------------------------------------------------------------ ----------------------
  Base excision repair (BER)                          11/139    0.002374441   BLM;RAD50; PARP4; RECQL5; LIG1; MPG; PARP2; ERCC4; PNKP; FANCG; POLH                                               GO biol process
  DNA 3\' dephosphorylation involved in DNA repair    10/120    0.002376199   BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; FANCG; POLH                                                   GO biol process
  DNA dealkylation involved in DNA repair             12/128    0.000983329   BLM; RAD50; PARP4; RECQL5; LIG1; MPG; MGMT; PARP2; ERCC4; PNKP; FANCG; POLH                                        GO biol process
  DNA ligation involved in DNA repair                 11/132    0.002374441   BLM; RAD50; PARP4; RECQL5; LIG1; MGMT; PARP2; ERCC4; PNKP; FANCG; POLH                                             GO biol process
  DNA repair                                          18/285    8.22494E-05   BLM; LIG1; CCNH; XRCC5; PARP2; MGMT; MPG; POLM; PNKP; FANCG; BRIP1; RAD50; NEIL2; ERCC4; ERCC2; ATM; ERCC5; POLH   Reactome
  DNA synthesis involved in DNA repair                12/142    0.001514863   BLM; BRIP1; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; ATM; FANCG; POLH                                       GO biol process
  Double-strand break repair (DSBR)                   12/164    0.002374441   BLM; BRIP1; RAD50; PARP4; RECQL5; LIG1; XRCC5; PARP2; ERCC4; PNKP; FANCG; POLH                                     GO biol process
  Mismatch repair (MMR)                               10/140    0.005835867   BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; FANCG; POLH                                                   GO biol process
  Mitochondrial DNA repair                            10/123    0.002552586   BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; FANCG; POLH                                                   GO biol process
  Non homologous end joining (NHEJ)                   10/120    0.002376199   BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; FANCG; POLH                                                   GO biol process
  Nucleotide excision repair (NER)                    11/138    0.002374441   BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; ERCC2; FANCG; POLH                                            GO biol process
  Nucleotide phosphorylation involved in DNA repair   10/120    0.002376199   BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; FANCG; POLH                                                   GO biol process
  Homologous recombination (HR)                       10/132    0.00369711    BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; FANCG; POLH                                                   GO biol process
  Single strand break repair (SSBR)                   11/124    0.001805921   BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; APTX; FANCG; POLH                                             GO biol process
  UV-damage excision repair                           11/158    0.003533915   BLM; RAD50; PARP4; RECQL5; LIG1; PARP2; ERCC4; PNKP; EIF2AK4; FANCG; POLH                                          GO biol process
  XPC complex (NER)                                   15/160    8.19637E-06   WWOX; CCNH; XRCC5; MGMT; CD3EAP; FANCG; POC5; ERCC4; ERCC2; MDM2; OBFC1; ATM; ERCC5; POLH; UGT1A6                  Jenesen compartments

FDR: false discovery rate.

In particular, many sarcoma risk genes appear to be involved in all main DNA repair pathways, including single strand break repair pathways (base excision repair \[BER\], nucleotide excision repair \[NER\], mismatch repair \[MMR\]) and double strand repair pathways (non homologous end joining \[NHEJ\], homologous recombination \[HR\]).

DISCUSSION {#s3}
==========

We described the findings of the first field synopsis and meta-analysis dedicated to the relationship between germline DNA variation and risk of developing bone and soft tissue sarcomas, which is based on genotyping data from 90 studies enrolling almost 48,000 people with a control-to-case ratio equal to 2. The resulting knowledgebase will be hosted by our cancer-dedicated website (at [www.mmmp.org](http://www.mmmp.org)) \[[@R100]\] as a freely available online data repository that will be annually updated.

Overall, our findings support the hypothesis that genetic polymorphism does contribute to sarcoma susceptibility. This is exemplified by the population attributable risk (PAR=37.2%) calculated for three SNPs associated with the risk of sarcoma at a high level of evidence (rs11599754 of *ZNF365/EGR2*, rs231775 of *CTLA4*, and rs454006 of *PRKCG*), which indicates that more than one third of sarcoma cases would not occur in a hypothetical population where these three risk variants were absent. This remarkable influence of just three SNPs is linked not only to the high frequency of the risk alleles but also to the interesting fact that the risk, defined as odds ratio, associated with single variants ranged between 1.35 and 1.48, which are values higher than those usually observed for other malignancies such as breast \[[@R101]\], colorectal \[[@R102]\], and gastric carcinomas \[[@R103]\], which generally include odds ratios between 1.10 and 1.30. Considering that the mean risk among variants significantly associated with sarcoma predisposition was even higher (approximately 1.70, see Table [2](#T2){ref-type="table"}), one might speculate that germline DNA variation is especially important in the determinism of the susceptibility to this family of tumors.

Overall, the quality of the available data, which was thoroughly assessed by means of both Venice criteria and false positive report probability (FPRP), was satisfactory considering that the statistically significant evidence on 47 of 55 variants for which a meta-analysis was feasible was classified as high to moderate level of quality with 10 SNPs considered adequate according to the FPRP (Table [2](#T2){ref-type="table"}). A statistically significant association was also demonstrated for additional 906 SNPs, for which only a single data source was available, which pinpoints the urgent need for replication studies in order to validate or refute these findings.

Conventional meta-analysis of single variants led us to identify 55 SNPs significantly associated with sarcoma risk (Table [2](#T2){ref-type="table"}), and additional 53 SNPs were reported in single studies (Table [3](#T3){ref-type="table"}): these variants are linked to a variety of genes whose protein products are involved in several cell activities. Therefore, we tried to provide readers with a preliminary interpretation of these findings from the functional biology viewpoint. Using modern SNP-to-gene and gene-to-function approaches such as integrative analysis of genetic variation with expression quantitative trait locus (eQTL) data \[[@R9]\] and respectively pathway/network analysis \[[@R8]\], we hypothesize that germline variation of the DNA repair machinery might be of special relevance for the development of this type of cancer (Figure [2](#F2){ref-type="fig"}). This finding -- which has been very recently confirmed in patients with Ewing\'s sarcoma \[[@R104]\] - is in line with the complex gene and chromosome abnormalities that characterized some sarcoma histologies, as well as with the epidemiological observation that people accidentally \[[@R105]\] or therapeutically \[[@R106]\] exposed to ionizing radiations and thus prone to develop DNA damage are at higher risk of different types of sarcomas. In this regard, it is interesting to note that peripheral blood mononuclear cells of patients diagnosed with sarcomas show a higher sensitivity to mutagens *in vitro* as compared to controls \[[@R107]\], which supports the hypothesis that the genetic background can make the difference on an individual basis in terms of response to environmental carcinogens potentially involved in sarcomagenesis.

Finally, also somatic DNA alterations appear to confer a defective DNA repair capability to some sarcoma types such as Ewing\'s sarcoma \[[@R108]\], and thus the combinatory study of germline and somatic DNA variations characterizing sarcomas might lead to better understand the cascade of molecular events underlying sarcomagenesis, as recently proposed for the *EWSR1-FLI1* fusion gene and the SNPs near *EGR2* in Ewing\'s sarcoma patients \[[@R29]\].

Overall, these converging data suggest that more investigation aimed to fully elucidate whether the germline individual capacity of repairing genomic damage can actually affect the predisposition to a complex and heterogeneous trait such as sarcomas might be particularly fruitful.

In our work we also confirmed the association between sarcoma risk and variants of single genes, such as *ZNF365, ADO, EGR2, CTLA4, TP53, CD86, NUDT6, MDM2, ERCC5* and *ADAMTS6* just to mention the top ten by statistical significance. Many of these genes are not known to be involved in DNA repair and thus the relationship between these single gene findings and network/pathway analysis might appear of unclear interpretation and doubtful importance. However, we must remember that current evidence (and thus our analysis) is based on 88 candidate gene studies and only two GWAS: therefore, more extensive investigation is needed on the variation of pathways for which data on single genes are currently available. In this regard, our meta-analysis data can be utilized to inform future studies on candidate pathways whose genetic variation could affect sarcoma susceptibility.

This systematic review also underscores the main limitation of the evidence on the genetic susceptibility of sarcomas. In fact, most of current information is driven by data from studies investigating bone tumors (78 of 90, 86.6%). Studies focusing on soft tissue sarcomas are thus eagerly awaited, the formation of international consortia being advocated in order to overcome the hurdle of disease rarity. Hopefully, technological improvements in direct DNA sequencing such as next generation sequencing (NGS) methods will further accelerate the discovery pace in this field of investigation, as recently reported \[[@R104]\].

Nevertheless, we also recognize some limitations of this synopsis: data from different tumor types and population ethnicity were pooled together to find associations despite the diversity of sarcoma histologies, leading to high level of between-study heterogeneity. To overcome to this limitation we performed subgroup and sensitivity analysis whenever possible. Moreover, despite our efforts to avoid the issue of overlapping series, it is always possible that partial overlaps between multiple series published by the same research groups that cannot be detected by full text reading did remain included in pooled analyses: however, we believe that the influence of this potential residual overlapping on the overall results is reasonably low.

In conclusion, we hope that the creation of the first knowledgebase dedicated to the relationship between germline DNA variation and sarcoma risk can not only represent a valuable reference for investigators involved in sarcoma research but also inform future studies based on the gaps of the current literature.

MATERIALS AND METHODS {#s4}
=====================

Search strategy, eligibility criteria, quality score assessment and data extraction {#s4_1}
-----------------------------------------------------------------------------------

This study followed the principles proposed by the Human Genome Epidemiology Network (HuGeNet) for the systematic review of molecular association studies \[[@R109]\].

We considered eligible all the studies concerning the association between any genetic variant and the predisposition to sarcoma in humans, providing the raw data necessary to calculate risk of developing a sarcoma or the summary data. Exclusion criteria were: virus-induced sarcomas (HHV8 - Kaposi sarcoma); sarcomas secondary to radiation therapy; sarcomas secondary to burns/scars/surgery; associations between mitochondrial DNA variations and sarcomas; gastrointestinal stromal tumors (GIST).

Database search of original articles analyzing the association between any genetic variant and susceptibility to sarcoma was conducted independently by two investigators though the following database: MEDLINE (via the PubMed gateway); The Cochrane Library; Scopus; Web of Science. The search included the following three groups of keywords: 1) sarcoma, solitary fibrous tumor, chordoma, tenosynovitis, fibromatosis, desmoids, myofibroblastic, myopericytoma, myxoma, Ewing, desmoplastic, PEComa, haemangioendothelioma, lymphangioma, myoepithelioma; 2) risk, sarcomagenesis, tumorigenesis, predisposition, susceptibility; 3) polymorphism, SNP, variant, genome wide association study and its acronym GWAS. Searches were conducted using all combinations of at least one keyword from each group. References from eligible articles were also used to refine the literature search.

The quality of the studies was evaluated according to Newcastle-Ottawa quality assessment scale (NOS) \[[@R110]\]. In brief, the following three parameters were evaluated with a "star system": the selection of the study groups (0 to 4 "stars"), the comparability of the groups (0 to 2 "stars"), and the ascertainment of either the exposure or outcome of interest for case-control or cohort studies respectively (0 to 3 "stars"). The maximum total score was 9 "stars" and represented the highest quality.

Data were extracted independently by two investigators using a template. Every disagreement was resolved by a third investigator in order to reach consensus. Authors were contacted whenever unreported data were potentially useful to enable the inclusion of the study into the systematic review. The data extracted from eligible studies were: authors, journal, year of publication, region or country where the study was conducted, hospital where the patients were diagnosed, number of patients with sarcoma enrolled and healthy control subjects, period of enrolment, prevalent ethnicity (\>80%, categorized in Caucasian, Asian, African and mixed), subjects age, genetic polymorphisms and allelic frequency in both cases and controls (if no raw data were available, summary data were collected, i.e. odds ratios and confidence intervals), study design (population-based versus hospital-based), statistical methods used, and sarcoma histology.

We considered data published in different articles by the same Author/s with the same (or similar) number of subjects enrolled in the same period of time in the same hospital, to be derived by the same group of patients. In publications with either overlapping cases or controls, the most recent or largest population was chosen.

For analysis purposes, the search was closed in August 2017.

Statistical analysis {#s4_2}
--------------------

We calculated summary odds ratios (ORs) and their corresponding 95% confidence intervals (95%CI) starting from raw data to measure the strength of association between each polymorphism and sarcoma risk.

Whenever possible, we calculated the pooled ORs assuming 3 different genetic models: per-allele (additive), dominant and recessive. If the included studies reported exclusively per-allele ORs, as in GWAS, we calculated the pooled OR assuming the per-allele (additive) model.

Random effects meta-analysis based on the inverse variance method was used to calculate summary ORs; this model reduces to a fixed effect meta-analysis if between-study heterogeneity is absent. We chose this model for the large between-study heterogeneity usually expected in genetic association studies. A meta-analysis was performed only if at least two independent data sources were available. In case of GWAS, we considered as data source the joint analysis between the discovery and the validation phases. Subgroup analysis by histological subtype (Ewing\'s sarcoma vs osteosarcoma) was planned if data permitted.

Regarding ethnicity, analyses were divided in 4 groups: African (if the datasets were all African population-based), Asian (if the datasets were all Asian population-based), Caucasian (if the datasets were all Caucasian population-based), and mixed (if the datasets were African, Asian and Caucasian or if the datasets were from mixed ethnicity). In order to test any dominant study driving effect, sensitivity analysis by ethnicity (Asian vs Caucasian/other) was performed in mixed meta-analyses, with more than two datasets, excluding either the Asian study or the Caucasian study from the meta-analysis.

Between-study heterogeneity was formally assessed by the Cochran Q-test and the I-squared statistic, the latter indicating the proportion of the variability in effect estimates linked to true between-study heterogeneity as opposed to within-study sampling error.

All statistical analyses were performed with RevMan 5 (Review Manager computer program, version 5.3; Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Assessment of cumulative evidence {#s4_3}
---------------------------------

With the aim to assess the credibility of statistically significant associations based on the results of data meta-analysis, we used the Venice criteria \[[@R111]\]. In brief, we defined credibility levels based on the strength (classified as A=strong, B=moderate or C=weak) of three following parameters: amount of the evidence, replication of the association and protection from bias. We graded the amount of evidence, which approximately depends on the study sample size, based on the sum of cases and controls. Grade A, B or C was assigned to meta-analyses with total sample size \>1000, 100--1000 and \<100, respectively. Also, the replication of the association was graded considering the amount of between-study heterogeneity. We assigned grade A, B or C to meta-analyses with I-squared \<25%, 25--50% and \>50%, respectively. We graded protection from bias as A if no bias was observed, B if bias was potentially present or C if bias was evident. While assessing protection from bias we also considered the magnitude of the association. We assigned a score of C to an association characterized by a summary OR\<1.15 or a summary OR\>0.87 if the effect of the polymorphism was protective.

In addition to the Venice criteria, we assessed the noteworthiness of significant findings by calculating the false positive report probability (FPRP) \[[@R112]\], which is defined as the probability of no true association between a genetic variant and disease (null hypothesis) given a statistically significant finding. FPRP is based not only on the observed P-value of the association test but also on the statistical power of the test and on the prior probability that the molecular association is real following a Bayesian approach. We calculated FPRP values for two levels of prior probabilities: at a low prior (10E-3) that would be similar to what is expected for a candidate variant, and at a very low prior (10E-6) that would be similar to what would be expected for a random variant. To classify a significant association as 'noteworthy', we used a FPRP cut-off value of 0.2.

Overall, we defined the credibility level of the cumulative evidence as high (Venice criteria A grades only coupled with "noteworthy" finding at FPRP analysis), low (one or more C grades combined with lack of noteworthiness), or intermediate (for all other combinations).

To estimate the impact of genetic variation on the risk of sarcomas, we calculated the so called population attributable risk (PAR) using the following formula:

Pr (RR − 1)/\[1 + Pr (RR − 1)\],

where Pr is the proportion of control subjects exposed to the allele of interest and the relative risk (RR) was estimated using the summary estimates (i.e. ORs) calculated by the meta-analysis. The joint PAR for combinations of polymorphisms was calculated as follows:

1 − (∏~1→n~\[1 − PARi\]),

where PARi corresponds to the individual PAR of the *i*th polymorphism and *n* is the number of polymorphisms considered \[[@R113]\].

Network and pathway analysis {#s4_4}
----------------------------

In order to explore the mechanisms underlying the pathogenesis of sarcomas, we utilized network and pathway analysis to test the hypothesis that genes whose variations are associated with sarcoma risk interact with each other possibly within the frame of some specific molecular pathways \[[@R8]\].

To this aim, we first selected SNPs significantly associated with sarcoma risk. In case of SNPs located in intergenic regions we selected the first closest and the second closest genes, not necessarily upstream and downstream of the SNPs of interest.

Since most SNPs are intergenic or intronic and thus no obvious functional effect can be inferred, expression quantitative trait locus (eQTL) analysis was used to identify genes whose expression is affected by DNA variants \[[@R114]\]. The resulting gene list was the input for both network and pathway analysis.

For the former, the STRING web server was employed to study protein-protein interaction (PPI) across the selected genes \[[@R115]\], the confidence score being set \>0.4. As a measure of across network connectivity STRING provides the average node degree, where degree is the conceptually simplest centrality measure as it measures the number of edges between protein connections attached to a protein; moreover, STRING computes the PPI enrichment P-value, which is significant when input proteins have more interactions among themselves than what would be expected for a random set of proteins of similar size, drawn from the genome.

As regards pathway analysis, the Enrichr web server was utilized to identify in our list over-representation of genes involved in specific pathways described in dedicated databases \[[@R116]\]. Hypergeometric distribution with Fisher\'s exact test was used to calculate the statistical significance of gene overlapping, followed by correction for multiple hypotheses testing using the false discovery rate \[FDR\] method.
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